Senseonics Holdings (SENS) Reports Q1 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Senseonics Holdings, Inc. Reports First Quarter 2016 Financial Results
May 12, 2016 4:15 PM EDTGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the first quarter ended March 31, 2016.
RECENT HIGHLIGHTS & ACCOMPLISHMENTS:
Initiated the multi-center PRECISE II pivotal clinical trial in the United States to demonstrate safety and effectiveness of the EversenseTM Continuous Glucose Monitoring System. Completed enrollment for the U.S. pivotal trial being conducted at 8 sites and including 90... More